KR20070007076A - 술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형 - Google Patents

술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형 Download PDF

Info

Publication number
KR20070007076A
KR20070007076A KR1020067015502A KR20067015502A KR20070007076A KR 20070007076 A KR20070007076 A KR 20070007076A KR 1020067015502 A KR1020067015502 A KR 1020067015502A KR 20067015502 A KR20067015502 A KR 20067015502A KR 20070007076 A KR20070007076 A KR 20070007076A
Authority
KR
South Korea
Prior art keywords
sae
amino
corticosteroid
hydroxy
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067015502A
Other languages
English (en)
Korean (ko)
Inventor
디. 핍킨 제임스
오. 짐메르엘 루퍼트
오. 톰프슨 다이앤
엘. 모쉐 게롤드
Original Assignee
사이덱스 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이덱스 인크 filed Critical 사이덱스 인크
Publication of KR20070007076A publication Critical patent/KR20070007076A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020067015502A 2003-12-31 2004-12-31 술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형 Ceased KR20070007076A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53362803P 2003-12-31 2003-12-31
US60/533,628 2003-12-31

Publications (1)

Publication Number Publication Date
KR20070007076A true KR20070007076A (ko) 2007-01-12

Family

ID=34794240

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020067015502A Ceased KR20070007076A (ko) 2003-12-31 2004-12-31 술포알킬 에테르 γ-시클로덱스트린 및코르티코스테로이드를 함유한 흡입용 제형
KR1020067015501A Withdrawn KR20070005586A (ko) 2003-12-31 2004-12-31 단위 용량 현탁액으로부터 제조된 술포알킬 에테르시클로덱스트린 및 코르티코스테로이드를 함유한 흡입용제형
KR1020067015494A Ceased KR20070007075A (ko) 2003-12-31 2004-12-31 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020067015501A Withdrawn KR20070005586A (ko) 2003-12-31 2004-12-31 단위 용량 현탁액으로부터 제조된 술포알킬 에테르시클로덱스트린 및 코르티코스테로이드를 함유한 흡입용제형
KR1020067015494A Ceased KR20070007075A (ko) 2003-12-31 2004-12-31 술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형

Country Status (15)

Country Link
EP (4) EP3238708A1 (cg-RX-API-DMAC7.html)
JP (6) JP2007517069A (cg-RX-API-DMAC7.html)
KR (3) KR20070007076A (cg-RX-API-DMAC7.html)
CN (3) CN1976679B (cg-RX-API-DMAC7.html)
AU (3) AU2004312096A1 (cg-RX-API-DMAC7.html)
BR (3) BRPI0418386A (cg-RX-API-DMAC7.html)
CA (3) CA2551749C (cg-RX-API-DMAC7.html)
DK (1) DK1732512T3 (cg-RX-API-DMAC7.html)
HU (1) HUE032527T2 (cg-RX-API-DMAC7.html)
IL (6) IL176576A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA06007581A (cg-RX-API-DMAC7.html)
NZ (1) NZ548225A (cg-RX-API-DMAC7.html)
PT (1) PT1732512T (cg-RX-API-DMAC7.html)
RU (3) RU2006127432A (cg-RX-API-DMAC7.html)
WO (3) WO2005065435A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0510119A (pt) 2004-04-23 2007-09-25 Cydex Inc formulação para dpi contendo sulfoaquil éter de ciclodextrina
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
SI2952197T1 (sl) 2005-10-26 2017-09-29 Cydex Pharmaceuticals, Inc. Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
EP2623113B1 (en) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
US20070111965A1 (en) * 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
EP1959953A2 (en) * 2005-12-02 2008-08-27 Alembic Limited Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
EP1971346A2 (en) * 2005-12-20 2008-09-24 Tika Läkemedel AB Systems and methods for the delivery of corticosteroids
PL1971369T3 (pl) * 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
NZ571537A (en) * 2006-04-03 2012-06-29 Nutramax Lab Inc Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1894559A1 (en) * 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US20090149432A1 (en) * 2007-11-09 2009-06-11 Shrewsbury Stephen B Methods for administering corticosteroid formulations
RU2363473C1 (ru) * 2008-02-18 2009-08-10 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ антифлогистической активации в эксперименте
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンを用いた併用療法
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
AU2010217297A1 (en) * 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
CA2765221C (en) 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
CN102188371B (zh) * 2011-05-11 2013-01-23 台州职业技术学院 一种环索奈德纳米粒水溶液及其制备方法
CN102973574A (zh) * 2011-09-02 2013-03-20 北京燕锋晨医药技术发展有限公司 一种用于治疗哮喘的药物组合物及制备方法
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2013259573B2 (en) * 2012-05-08 2018-02-15 Onyx Therapeutics, Inc. Cyclodextrin complexation Methods for Formulating Peptide Proteasome Inhibitors
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2506080C1 (ru) * 2012-09-25 2014-02-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО НижГМА Минздравсоцразвития России) Способ лечения и профилактики осложнений в полости рта, вызванных приемом ингаляционных гормональных препаратов у больных бронхиальной астмой
RU2493827C1 (ru) * 2012-10-03 2013-09-27 Шолекс Девелопмент Гмбх Стабильный комбинированный раствор фенотерола гидробромида и ипратропия бромида
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
EP2923702A1 (en) * 2014-03-28 2015-09-30 Universite De Liege Composition of cyclodextrin with budesonide derivatives for treatment and prevention of pulmonary inflammatory disease
KR20170129126A (ko) * 2015-02-13 2017-11-24 벤더르빌트 유니버시티 밀리논 조성물 및 이를 투여하기 위한 방법
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
WO2017193110A1 (en) * 2016-05-06 2017-11-09 Stites Adam Cannabinoid compositions for sublingual spray nebulizer
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EA202000218A1 (ru) * 2018-01-23 2021-03-03 Александр Григорьевич ЧУЧАЛИН Фармацевтическая композиция (варианты), применение фармацевтической композиции (варианты)
KR20250171439A (ko) 2019-08-01 2025-12-08 인카다 테라퓨틱스, 인크. 항부정맥 제제
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CA3171958A1 (en) * 2020-03-18 2021-09-23 Memorial Sloan Kettering Cancer Center Inhalational therapy for covid-19
EP4121116A4 (en) * 2020-03-19 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education STABILIZATION OF COMPOUNDS AS CYCLODEXTRIN COMPLEXES
CN115835885B (zh) * 2020-06-23 2025-02-07 广州谷森制药有限公司 包含奥达特罗和布地奈德的药物组合物的制备
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
CN113018280A (zh) * 2021-03-01 2021-06-25 石家庄四药有限公司 一种异丙托溴铵吸入用溶液制剂及其制备方法
CN121466042A (zh) * 2026-01-09 2026-02-06 苏州市立医院 一种吸入用药物组合物及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008875A (en) * 1960-01-08 1961-11-14 Upjohn Co Neomycin and mirystyl-gamma-picolinium halide compositions
NL289785A (cg-RX-API-DMAC7.html) * 1962-11-29
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5510339A (en) 1993-02-02 1996-04-23 Mayo Foundation For Medical Education And Research Method for the treatment of bronchial asthma by administration of topical anesthetics
NZ263084A (en) 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
EP1283035A3 (en) 1994-12-22 2003-03-19 AstraZeneca AB Therapeutic preparation for inhalation containing parathyroid hormone
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
JP2001503406A (ja) * 1996-10-28 2001-03-13 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ 医薬組成物
US6071910A (en) 1996-12-05 2000-06-06 Mayo Foundation For Medical Education And Research Use of agents to treat eosinophil-associated pathologies
US5837713A (en) 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2257795T3 (es) 1997-07-01 2006-08-01 Pfizer Products Inc. Procedimiento para producir una ciclodextrina.
US20020010197A1 (en) 1998-01-13 2002-01-24 John Dixon Pharmaceutical compositions comprising a compound having dopamine (d2) receptor agonist activity and a compound (b) having beta2-adrenoreceptor agonist activity
WO1999042111A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
CA2332369A1 (en) * 1998-05-27 1999-12-02 Euroceltique S.A. Drug delivery system comprising a tightly compacted solid medicament stock
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
WO2000012137A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
FR2789685B1 (fr) 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
DE60025019T2 (de) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6479467B1 (en) 1999-12-16 2002-11-12 Eastman Chemical Company Cyclodextrin ethers
RU2180217C2 (ru) 2000-03-21 2002-03-10 Закрытое акционерное общество "Пульмомед" Стабильный водный раствор противовоспалительного действия, содержащий будесонид
AU2001255709A1 (en) 2000-05-11 2001-11-20 Eastman Chemical Company Acylated cyclodextrin guest inclusion complexes
WO2002055562A2 (en) 2001-01-11 2002-07-18 Eastman Chem Co Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US7026304B2 (en) 2001-02-14 2006-04-11 Akzo Nobel N.V. 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
AU2003217623A1 (en) * 2002-02-20 2003-09-09 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
BR0315198A (pt) 2002-10-09 2005-08-30 Insert Therapeutics Inc Materiais e composições à base de ciclodextrina e usos relacionados aos mesmos

Also Published As

Publication number Publication date
AU2004312095A1 (en) 2005-07-21
EP1732512A4 (en) 2008-07-23
AU2004311478A1 (en) 2005-07-21
RU2006127443A (ru) 2008-02-10
CA2551749A1 (en) 2005-07-21
EP1732512A2 (en) 2006-12-20
CN1976679A (zh) 2007-06-06
JP2015129173A (ja) 2015-07-16
DK1732512T3 (en) 2017-07-10
AU2004312096A1 (en) 2005-07-21
NZ548225A (en) 2012-12-21
CA2552641A1 (en) 2005-07-21
EP1729724A4 (en) 2008-07-23
CN1921830A (zh) 2007-02-28
CN1921834A (zh) 2007-02-28
WO2005065435A3 (en) 2005-09-01
WO2005065649A1 (en) 2005-07-21
EP1729724A1 (en) 2006-12-13
IL176577A0 (en) 2006-10-31
EP3238708A1 (en) 2017-11-01
JP2012224648A (ja) 2012-11-15
IL251496B (en) 2021-04-29
JP5782413B2 (ja) 2015-09-24
EP1718276A2 (en) 2006-11-08
EP1732512B1 (en) 2017-03-22
MX348041B (es) 2017-05-25
IL176575A0 (en) 2006-10-31
PT1732512T (pt) 2017-07-24
BRPI0418276A (pt) 2007-05-02
EP1718276A4 (en) 2008-07-23
BRPI0418386A (pt) 2007-05-22
IL225946A0 (en) 2013-06-27
JP2007517068A (ja) 2007-06-28
IL176576A0 (en) 2006-10-31
IL251496A0 (en) 2017-05-29
JP2007517067A (ja) 2007-06-28
WO2005065435A2 (en) 2005-07-21
KR20070007075A (ko) 2007-01-12
RU2390330C2 (ru) 2010-05-27
BRPI0418276B1 (pt) 2017-02-14
CN1976679B (zh) 2011-08-31
RU2388462C2 (ru) 2010-05-10
JP6186478B2 (ja) 2017-08-23
RU2006127432A (ru) 2008-02-10
JP2007517069A (ja) 2007-06-28
JP2016172774A (ja) 2016-09-29
BRPI0418232A (pt) 2007-04-27
IL225946A (en) 2017-04-30
MXPA06007581A (es) 2007-03-09
HUE032527T2 (en) 2017-09-28
WO2005065651A1 (en) 2005-07-21
BRPI0418276B8 (pt) 2021-05-25
KR20070005586A (ko) 2007-01-10
CA2551749C (en) 2014-02-11
RU2006127467A (ru) 2008-02-10
CA2551826A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US10799599B2 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP6186478B2 (ja) スルホアルキルエーテルシクロデキストリンおよびコルチコステロイドを含む吸入製剤
US20110008325A1 (en) Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension
WO2008005692A2 (en) INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
MXPA06007583A (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
AU2014227557A1 (en) Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000